Inovio Pharmaceuticals (INO)
NASDAQ:INO
INO Stock Chart & Stats
$1.61
-$0.22(-9.65%)
At close: 4:00 PM EST
$1.61
-$0.22(-9.65%)
Day’s Range― - ―
52-Week Range$1.30 - $2.98
Previous CloseN/A
Volume1.36M
Average Volume (3M)780.02K
Market Cap
$111.24M
Enterprise Value$9.41B
Total Cash (Recent Filing)$58.51M
Total Debt (Recent Filing)$9.37B
Price to Earnings (P/E)―
Beta1.70
Next Earnings
May 12, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding69,091,960
10 Day Avg. Volume793,363
30 Day Avg. Volume780,025
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)33.86
Price to Sales (P/S)12485.24
P/FCF Ratio>-0.01
Enterprise Value/Market Cap84.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-91.18
Forecast
1Y Price Target
$4.50Price Target Upside179.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.39
Revenue Forecast (FY)$10.88M
Bulls Say, Bears Say
Bulls Say
BLA Acceptance And PDUFA DateFDA acceptance of the Biologics License Application with an assigned PDUFA goal date establishes a defined regulatory review timeline that could lead to approval and market entry for INO-3107.
Clinical Validation And PartnershipsA published Phase 1 proof-of-concept showing long-acting, scalable, tolerable DNA-delivered antibody activity and a clinical collaboration to test a combined glioblastoma therapy support the platform's therapeutic potential and development momentum.
Commercial Differentiation And DistributionINO-3107's lack of cold chain requirements and avoidance of additional surgical procedures during dosing could enable broader distribution and easier patient access compared with current RRP treatments.
Bears Say
Accelerated Approval Eligibility ConcernsFDA feedback that the submission lacks adequate information for accelerated approval eligibility creates regulatory uncertainty about pursuing a faster approval pathway for INO-3107.
Approval Timing Risk And Investor ImpactUncertainty around accelerated approval eligibility may extend review duration and delay commercialization, increasing execution risk and potential pressure on the stock if milestone-driven revenue expectations are deferred.
Data Sufficiency And Potential For Additional StudiesNoted deficiencies in supporting data could require submission of additional analyses or new clinical data, raising the likelihood of longer development timelines and higher program costs.
Inovio Pharmaceuticals News
INO FAQ
What was Inovio Pharmaceuticals’s price range in the past 12 months?
Inovio Pharmaceuticals lowest stock price was $1.30 and its highest was $2.98 in the past 12 months.
What is Inovio Pharmaceuticals’s market cap?
Inovio Pharmaceuticals’s market cap is $111.24M.
When is Inovio Pharmaceuticals’s upcoming earnings report date?
Inovio Pharmaceuticals’s upcoming earnings report date is May 12, 2026 which is in 43 days.
How were Inovio Pharmaceuticals’s earnings last quarter?
Inovio Pharmaceuticals released its earnings results on Mar 12, 2026. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of -$0.358 by $0.418.
Is Inovio Pharmaceuticals overvalued?
According to Wall Street analysts Inovio Pharmaceuticals’s price is currently Undervalued.
Does Inovio Pharmaceuticals pay dividends?
Inovio Pharmaceuticals pays a Monthly dividend of $0.069 which represents an annual dividend yield of N/A. See more information on Inovio Pharmaceuticals dividends here
What is Inovio Pharmaceuticals’s EPS estimate?
Inovio Pharmaceuticals’s EPS estimate is -0.35.
How many shares outstanding does Inovio Pharmaceuticals have?
Inovio Pharmaceuticals has 69,091,960 shares outstanding.
What happened to Inovio Pharmaceuticals’s price movement after its last earnings report?
Inovio Pharmaceuticals reported an EPS of $0.06 in its last earnings report, beating expectations of -$0.358. Following the earnings report the stock price went down -1.19%.
Which hedge fund is a major shareholder of Inovio Pharmaceuticals?
Currently, no hedge funds are holding shares in INO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inovio Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.50 (179.50% Upside)
$4.50 (179.50% Upside)
Blogger Sentiment
Bullish
INO Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 126.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Bearish
Bullish news 25%
Bearish news 75%
Bearish news 75%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.52%
12-Months-Change
Fundamentals
Return on Equity
-353.36%
Trailing 12-Months
Asset Growth
-34.13%
Trailing 12-Months
Company Description
Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
INO Company Deck
INO Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed meaningful clinical and regulatory progress for INO-3107 (BLA acceptance, PDUFA date, strong efficacy and differentiated safety/regimen) and tangible cost discipline that extended runway, alongside platform and partnership advancement. However, material risks remain: the FDA's preliminary concern about accelerated approval eligibility introduces regulatory uncertainty; the company experienced a ~37.8% decline in cash year-over-year, sustained large annual net losses, and relied on a noncash Q4 gain that masks operating results. Management has prioritized resources toward the October PDUFA date and partnerships for other programs, balancing progress with financial and regulatory challenges.View all INO earnings summariesINO Stock 12 Month Forecast
Average Price Target
$4.50
▲(179.50% Upside)
Technical Analysis
Ownership Overview
0.49% Insiders
5.22% Mutual Funds
12.20% Other Institutional Investors
77.80% Public Companies and
Individual Investors